← Back to Search

Other

High-Dose Vitamin C + Low-Dose Melphalan for Multiple Myeloma

Phase 1
Recruiting
Led By Christopher Strouse, MD
Research Sponsored by Michael Tomasson
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of multiple myeloma per IMWG criteria
Prior treatment must include a proteasome inhibitor, an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 28 days after the end of treatment
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing if a low dose of melphalan combined with high doses of ascorbate acid is safe and effective in treating patients who have multiple myeloma that has returned or does not respond to treatment.

Who is the study for?
This trial is for adults with multiple myeloma who've tried at least three prior treatments, including specific inhibitors and antibodies. They must have measurable disease progression but not be suitable for other beneficial regimens. Participants need good organ function, no severe comorbidities or certain infections, and can't be on warfarin or have a history of significant kidney stones.Check my eligibility
What is being tested?
The study tests high doses of Vitamin C (ascorbic acid) combined with low dose melphalan chemotherapy in patients whose multiple myeloma has relapsed after previous treatments. It's an early-phase trial focusing on safety and initial signs of effectiveness.See study design
What are the potential side effects?
Potential side effects include those typical of chemotherapy like nausea, fatigue, hair loss, increased risk of infection due to lowered blood counts; plus possible kidney stone formation and interference with diabetes monitoring.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with multiple myeloma.
Select...
I have been treated with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody.
Select...
I am not a candidate for known effective treatments for my relapsed or refractory multiple myeloma.
Select...
My organs are functioning well.
Select...
My condition worsened after 3 or more treatments.
Select...
I am able to get out of my bed or chair and move around.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 28 days after the end of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 28 days after the end of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of treatment related adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
Secondary outcome measures
Categorize and quantify adverse events compared to historical control
Overall response rate based on International Myeloma Working Group (IMWG) criteria
Oxidative stress parameters in plasma through blood testing
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Low dose melphalan + high dose ascorbate acid (HDAA)Experimental Treatment2 Interventions
Patients will receive a test dose of 15g of HDAA prior to starting treatment dose. This will be mainly to rule out allergic reactions. HDAA + Melphalan: HDAA on day 1 and day 4 in combination with melphalan 12.5 mg/m2, followed by 2 additional doses of HDAA on day 2 and day 5. A 3 + 3 cohort method will be used for this study. After successfully completing the test dose, subjects will receive 50gms, 75gms and 100gms of ascorbate per infusion in 3 different cohorts. Dose modifications are not made for weight or body surface area.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Melphalan
2008
Completed Phase 3
~1500

Find a Location

Who is running the clinical trial?

Michael TomassonLead Sponsor
University of IowaOTHER
442 Previous Clinical Trials
878,662 Total Patients Enrolled
3 Trials studying Multiple Myeloma
123 Patients Enrolled for Multiple Myeloma
Christopher StrouseLead Sponsor

Media Library

Ascorbate (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03602235 — Phase 1
Multiple Myeloma Research Study Groups: Low dose melphalan + high dose ascorbate acid (HDAA)
Multiple Myeloma Clinical Trial 2023: Ascorbate Highlights & Side Effects. Trial Name: NCT03602235 — Phase 1
Ascorbate (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03602235 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In what health conditions is Ascorbate typically prescribed?

"Vitamin A deficiency is regularly treated with Ascorbate. This same medication can be beneficial for addressing a variety of other maladies, including catarrh, vitamin insufficiency and amyloidosis."

Answered by AI

Are there any adverse effects associated with ingesting Ascorbate?

"Currently, the evidence of Ascorbate's safety is limited, therefore giving it a score of 1 on our scale. This assessment was made due to this being an early Phase 1 trial with only meager data pointing towards efficacy and security."

Answered by AI

What is the sample size of this research project?

"Yes, clinicaltrials.gov confirms that this trial is actively looking for participants to join the study, which was first posted on March 5th 2019 and last updated on December 31st 2021. As of now, only 9 patients are being sought at a single site."

Answered by AI

Is enrollment for this experiment open at this moment?

"Affirmative. Clinicaltrials.gov states that the research study, which was initially posted on March 5th 2019, is now recruiting participants. A total of 9 individuals are required to be recruited from 1 site."

Answered by AI
~2 spots leftby Aug 2025